## BASF Bioresearch and Cambridge Antibody Technology. When Abbott

Laboratories, the incumbent that had acquired BASF, brought Humira

to market, in the early 2000s, it was one of several monoclonal

antibody treatments for rheumatoid arthritis. However, it was mired in

controversy because its potential side eﬀects were hard to isolate from

the progression of the disease. The Abbott team worked with patient

advocacy groups to raise awareness and debunk the treatment’s stigma.

This, of course, involved some competitive risk, since Abbott’s eﬀorts

would also make rival products more acceptable to consumers and

health care professionals. But the move positioned Humira as the go-to